Oxford announces DSMB’s recommendation for Phase III renal cancer study
Following its fourth interim review of the Trist study, the data safety monitoring board (DSMB) advised that TroVax administered according to the protocol will not meet the predefined
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.